Tom Brady Appointed Chief Wellness Officer of eMed
SPORTS
eMed Population Health has announced that seven-time Super Bowl champion Tom Brady has been appointed Chief Wellness Officer.
Outside of his prowess in professional football, Tom Brady is synonymous with longevity, discipline, and evidence-based health in the world of high-performance athletics . Now, the seven-time Super Bowl champion is bringing that "TB12 energy" to the corporate boardroom.
Today, eMed Population Health, the leading digital platform for clinically supervised weight management and GLP-1 therapies, announced that Brady has been named its Chief Wellness Officer.
A New Standard for Workforce Health
The appointment comes at a critical juncture for American employers. As demand for GLP-1 and GIP therapies (like Wegovy and Ozempic) skyrockets, many organizations are struggling with fragmented care and soaring costs.
Working alongside eMed CEO Linda Yaccarino, Brady will focus on raising awareness for a more accountable, medically-guided approach to population health.
“High-quality medical care should be accessible and delivered responsibly,” Brady said. “At eMed, the focus is improving population health at scale... These medications can be truly game-changing, but only when paired with the right clinical guidance.”
The eMed Edge: Adherence and Outcomes
While the market is flooded with "cash-pay shortcuts," eMed differentiates itself through a disciplined, clinician-led model. The results speak for themselves:
90%+ Adherence Rate: Far exceeding industry norms.
Proven Weight Loss: Employees in the program saw an average loss of 21 lbs in just six months.
Biomarker Improvement: 99% of members saw improvements in health markers like heart health and inflammation.
Unlike unmanaged programs, which often see adherence drop as low as 35%, eMed combines at-home blood collection, precision dosing, and real-time coaching to ensure long-term health rather than just short-term access.
Beyond Cosmetic: The Science of Longevity
According to Dr. Dyan Hes, Chief Medical Officer of eMed, GLP-1s are about more than weight loss; they are tools for healthy aging. “The data is clear: they help protect the heart, reduce inflammation, and may even support brain health,” she noted.
With the recent introduction of FDA-approved oral GLP-1 options, demand is only expected to grow. By partnering with Brady, eMed is signaling that the future of workplace health isn't just about providing a prescription, it’s about providing a performance-driven culture of longevity.